Overview

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Status:
RECRUITING
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Phase:
PHASE2
Details
Lead Sponsor:
Genentech, Inc.